208 related articles for article (PubMed ID: 31172513)
1. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
2. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
5. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract][Full Text] [Related]
6. Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M; Li J; Li X; Wu D; Montaño Figueroa E; Rodriguez MG; Hou M; Finelli C; Shi HX; Xiao Z; Oliva EN; Gercheva Kyuchukova L; Drummond M; Symeonidis A; Velazquez EJ; Rivoli G; Izquierdo M; Kolekar Y; Spallarossa P; Angelucci E
Br J Haematol; 2024 May; 204(5):2049-2056. PubMed ID: 38343073
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Huang L; Tian M; Liu Z; Liu C; Fu R
J Investig Med; 2022 Apr; 70(4):953-962. PubMed ID: 34921125
[TBL] [Abstract][Full Text] [Related]
8. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
9. Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study.
Cilloni D; Ravera S; Calabrese C; Gaidano V; Niscola P; Balleari E; Gallo D; Petiti J; Signorino E; Rosso V; Panuzzo C; Sabatini F; Andreani G; Dragani M; Finelli C; Poloni A; Crugnola M; Voso MT; Fenu S; Pelizzari A; Santini V; Saglio G; Podestà M; Frassoni F
Sci Rep; 2020 Jun; 10(1):9156. PubMed ID: 32514107
[TBL] [Abstract][Full Text] [Related]
10. Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A; Sargentini V; Cotugno F; Bontempi K; Beltrami G; Di Tucci AA; Riva M; Quaresmini G; Vallisa D; Finelli C; Borin L; Fazi P; Vignetti M; Angelucci E
Eur J Haematol; 2019 May; 102(5):442-443. PubMed ID: 30776156
[No Abstract] [Full Text] [Related]
11. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
Cappellini A; Mongiorgi S; Finelli C; Fazio A; Ratti S; Marvi MV; Curti A; Salvestrini V; Pellagatti A; Billi AM; Suh PG; McCubrey JA; Boultwood J; Manzoli L; Cocco L; Follo MY
FASEB J; 2020 Nov; 34(11):15400-15416. PubMed ID: 32959428
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
[TBL] [Abstract][Full Text] [Related]
16. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
18. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
[TBL] [Abstract][Full Text] [Related]
19. Iron toxicity - Its effect on the bone marrow.
Isidori A; Borin L; Elli E; Latagliata R; Martino B; Palumbo G; Pilo F; Loscocco F; Visani G; Cianciulli P
Blood Rev; 2018 Nov; 32(6):473-479. PubMed ID: 29699840
[TBL] [Abstract][Full Text] [Related]
20. Reactive oxygen species mediated T lymphocyte abnormalities in an iron-overloaded mouse model and iron-overloaded patients with myelodysplastic syndromes.
Chen J; Lu WY; Zhao MF; Cao XL; Jiang YY; Jin X; Xu P; Yuan TT; Zhang YC; Chai X; Meng JX; Li Q; Xiao X; Mu J; Li DG; Qi AP
Ann Hematol; 2017 Jul; 96(7):1085-1095. PubMed ID: 28421266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
